Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Jon C. Ogg | Jul 22, 2015 at 1:55 PM EDT

Biogen Faces Mixed Alzheimer’s Reception

It seems Biogen's closely watched Alzheimer's drug candidate, aducanumab, has fallen short of analyst and investor expectations.

Chris Lange | Jul 22, 2015 at 11:05 AM EDT

Is This the End for XOMA?

XOMA Corp. (NASDAQ: XOMA) stumbled in trading Wednesday morning, perhaps fell off a cliff might be more accurate.

Chris Lange | Jul 22, 2015 at 10:25 AM EDT

Is Thoratech Getting Enough Premium in its Buyout?

Both companies announced the approval for a definitive agreement in which St. Jude Medical will acquire Thoratec in a cash…

Jon C. Ogg | Jul 21, 2015 at 5:45 PM EDT

UnitedHealth Raises Over $10 Billion to Fund Catamaran Buyout

UnitedHealth Group has confirmed what investors were expecting with the sale of billions of dollars in debt.

Chris Lange | Jul 21, 2015 at 5:29 PM EDT

How Exelixis Used Good News to Raise Over $100 Million in New Capital

It appears that Exelixis assumed now would be the best time to dilute following its most recent successful in clinical…

Chris Lange | Jul 21, 2015 at 10:50 AM EDT

Does Novavax Have the Answer for Ebola in New Trial?

Novavax is on the precipice of vaccinating Ebola, or at least according to its most recent clinical trial.

Jon C. Ogg | Jul 20, 2015 at 4:01 PM EDT

How Analysts Rated Lantheus After Quiet Period Ended

ThinkstockLantheus Holdings, Inc. (NASDAQ: LNTH), which is the parent company of Lantheus Medical Imaging, saw its quiet period come to…

Jon C. Ogg | Jul 20, 2015 at 3:43 PM EDT

How Analysts View Glaukos After Its Quiet Period Ended

Wikimedia CommonsGlaukos Corporation (NYSE: GKOS) has been a strong performer since its initial public offering at the end of June.…

Jon C. Ogg | Jul 20, 2015 at 1:45 PM EDT

Is UnitedHealth Now Fully Valued?

One analyst report does indicate that UnitedHealth may be fully valued. Other reports are not anywhere close to that conservative.

Chris Lange | Jul 20, 2015 at 1:40 PM EDT

vTv Therapeutics Sets Expected Price Range for IPO

vTv Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

Chris Lange | Jul 20, 2015 at 11:20 AM EDT

Horizon Pharma Sees Record Quarter Ahead

Horizon Pharma announced Monday morning that it expects its second-quarter financial results will be of record proportion.

Chris Lange | Jul 20, 2015 at 10:35 AM EDT

Is Exelixis a Buyout Target Again?

The most recent clinical trial results may have put Exelixis back on the map as a potential buyout.

Paul Ausick | Jul 20, 2015 at 9:35 AM EDT

Top Health Care Earnings for the Week Ahead

Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been…

Lee Jackson | Jul 20, 2015 at 8:50 AM EDT

4 Large Cap Biotech Stocks to Buy Before Earnings

A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.

Jon C. Ogg | Jul 17, 2015 at 2:58 PM EDT

Has Teladoc Peaked or Just Pulled Back After a Hot IPO?

ThinkstockTeladoc, Inc. (NYSE: TDOC) was nothing short of a very hot initial public offering back at the start of July.…

1 … 255 256 257 258 259 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Biogen Faces Mixed Alzheimer’s Reception

Is This the End for XOMA?

Is Thoratech Getting Enough Premium in its Buyout?

UnitedHealth Raises Over $10 Billion to Fund Catamaran Buyout

How Exelixis Used Good News to Raise Over $100 Million in New Capital

Does Novavax Have the Answer for Ebola in New Trial?

How Analysts Rated Lantheus After Quiet Period Ended

How Analysts View Glaukos After Its Quiet Period Ended

Is UnitedHealth Now Fully Valued?

vTv Therapeutics Sets Expected Price Range for IPO

Horizon Pharma Sees Record Quarter Ahead

Is Exelixis a Buyout Target Again?

Top Health Care Earnings for the Week Ahead

4 Large Cap Biotech Stocks to Buy Before Earnings

Has Teladoc Peaked or Just Pulled Back After a Hot IPO?

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

SMH ETF Investors: Watch Hyperscaler Capex Guidance at July Earnings Calls

A $620,000 Portfolio That Pays More Than the Average Social Worker's Salary

The Average American Has Worked for 6 Employers and 23% Still Have Multiple Old Retirement Accounts, Fidelity's 2026 Study Finds

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

Health and Healthcare Articles

All Health and Healthcare Articles

Biogen Faces Mixed Alzheimer’s Reception

Is This the End for XOMA?

Is Thoratech Getting Enough Premium in its Buyout?

UnitedHealth Raises Over $10 Billion to Fund Catamaran Buyout

How Exelixis Used Good News to Raise Over $100 Million in New Capital

Does Novavax Have the Answer for Ebola in New Trial?

How Analysts Rated Lantheus After Quiet Period Ended

How Analysts View Glaukos After Its Quiet Period Ended

Is UnitedHealth Now Fully Valued?

vTv Therapeutics Sets Expected Price Range for IPO

Horizon Pharma Sees Record Quarter Ahead

Is Exelixis a Buyout Target Again?

Top Health Care Earnings for the Week Ahead

4 Large Cap Biotech Stocks to Buy Before Earnings

Has Teladoc Peaked or Just Pulled Back After a Hot IPO?

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

SMH ETF Investors: Watch Hyperscaler Capex Guidance at July Earnings Calls

Featured Reads

A $620,000 Portfolio That Pays More Than the Average Social Worker's Salary

The Average American Has Worked for 6 Employers and 23% Still Have Multiple Old Retirement Accounts, Fidelity's 2026 Study Finds